Geron Corporation

GERN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-83.5M $-174.6M $-184.1M $-141.9M $-116.1M $-75.6M $-68.5M $-27.0M
Depreciation & Amortization $474.0K $546.0K $442.0K $288.0K $215.0K $158.0K $64.0K —
Depreciation — — — — — $158.0K $64.0K $59.0K
Amortization — — — — — — — —
Stock-Based Compensation $26.7M $31.2M $18.5M $8.0M $8.1M $6.9M $6.1M $6.4M
Net Cash from Operating Activities $-111.0M $-218.6M $-167.7M $-127.4M $-95.6M $-66.7M $-43.8M $-21.0M
Investing Activities
Capital Expenditures — $680.0K $830.0K $431.0K $207.0K $401.0K $413.0K $16.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $107.2M $-106.0M $-180.3M $62.1M $71.9M $-105.3M $27.4M $-77.7M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $2.3M $334.4M $362.0M $87.3M $48.6M $168.3M $19.5M $93.0M
Net Change in Cash $-1.4M $9.7M $13.9M $22.0M $24.9M — — —
Free Cash Flow — $-219.3M $-168.6M $-127.8M $-95.8M $-67.1M $-44.2M $-21.0M
← Newer Page 1 of 3 Older →